Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Kitada M, Kanasaki K, Koya D. Clinical therapeutic strategies for early stage of diabetic kidney disease. World J Diabetes 2014; 5(3): 342-356 [PMID: 24936255 DOI: 10.4239/wjd.v5.i3.342]
World J Diabetes. Jun 15, 2014; 5(3): 342-356 Published online Jun 15, 2014. doi: 10.4239/wjd.v5.i3.342
Clinical therapeutic strategies for early stage of diabetic kidney disease
Munehiro Kitada, Keizo Kanasaki, Daisuke Koya
Munehiro Kitada, Keizo Kanasaki, Daisuke Koya, Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa 920-0293, Japan
Author contributions: All authors contributed to this work.
Supported by A Grant from Novo Nordisk Pharma, to Kitada M; A Grant-in-Aid for Scientific Research (C) to Kitada M, No. 24591218; A Grant for Promoted Research from Kanazawa Medical University to Kitada M, No. S2012-4; A Grant-in-Aid for Scientific Research (B) to Koya D, No. 25282028; A Grant-in-Aid for Challenging Exploratory Research to Koya D, No. 25670414; A grant for Specially Promoted Research from Kanazawa Medical University to Koya D, No. SR2012-06; and the 4th Annual Research Award Grant of the Japanese Society of Anti-Aging Medicine, to Koya D
Correspondence to: Daisuke Koya, MD, PhD, Department of Diabetology and Endocrinology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku-gun, Ishikawa 920-0293, Japan. koya0516@kanazawa-med.ac.jp
Telephone: +81-76-2862211 Fax: +81-76-2866927
Received: November 26, 2013 Revised: March 8, 2014 Accepted: April 17, 2014 Published online: June 15, 2014 Processing time: 202 Days and 8 Hours
Core Tip
Core tip: We show the significance of targeting the remission/regression of microalbuminuria in type 2 diabetic patients, leading to protection against the progression of diabetic kidney disease (DKD) and cardiovascular events. To achieve the remission/regression of microalbuminuria, the multifactorial intervention and the early detection of microalbuminuria with continuous screening is important, as management of DKD. Multifactorial intervention includes glucose, blood pressure and lipid control. Additionally, other therapies, including vitamin D receptor activation, uric acid-lowering medicine and incretin-related medicines may be promising for preventing the progression of DKD. We review the current standard treatment for DKD and other prospective therapies for DKD.
